MedTrace Logo

Activity Program During Aromatase Inhibitor Therapy

NCT03786198 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2023-06-27

No results posted yet for this study

Summary

The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant aromatase inhibitor (AI) therapy, can prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients.

Conditions

  • Early Breast Cancer

Interventions

BEHAVIORAL

Activity program

Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks

BEHAVIORAL

Control

Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Friedemann Honecker, MD · Tumor- und Brustzentrum ZeTuP St.Gallen

  • Nicolette Hoefnagels, MSc · Tumor- und Brustzentrum ZeTuP St.Gallen

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-28
Primary Completion
2021-09-27
Completion
2023-06-08

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786198 on ClinicalTrials.gov